Market Cap ₹54969 Cr.
Stock P/E 38.5
P/B 2.1
Current Price ₹411.2
Book Value ₹ 200.5
Face Value 5
52W High ₹423.1
Dividend Yield 0.12%
52W Low ₹ 290.8
Biocon Limited is an India-based biopharmaceutical company that focuses to deal with diabetes, cancers and autoimmune diseases. The Company is likewise focused on developing novel treatments for diabetes, oncology and immunology. The Company's corporations section includes Generics, Biosimilars, Novel Biologics and Research Services. The Company's Generic Formulations and API products consist of Rosuvastatin, Mycophenolate Mofetil (MMF), Glatiramer Acetate, Fingolimod, Teriflunomide, Dasatinib, Lenalidomide, Pazopanib, Erdafitinib Orlistat, Mirabegron, Simvastatin, Atorvastatin, Fingolimod, Dapagliflozin, Pemetrexed, Simvastatin, Atorvastatin, Rosuvastatin, Dabigatran, Apixaban, Vildagliptin, Linagliptin, Empagliflozin, Repaglinide, Liraglutide, Sirolimus, Pimecrolimus, Posaconazole, Micafungin, Anidulafungin and Brinzolamide. The Company's portfolio consists of ALZUMAb-L (Itolizumab), RemWin (Remdesivir), ARAFLU (Favipiravir) and CytoSorb.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 3423 | 3462 | 3954 | 3917 | 3433 | 3590 | 3821 | 4417 | 3942 | 4296 |
| Other Income | 94 | 158 | 566 | 49 | 1135 | 33 | 35 | 37 | 80 | 93 |
| Total Income | 3516 | 3620 | 4519 | 3966 | 4567 | 3623 | 3856 | 4454 | 4022 | 4389 |
| Total Expenditure | 2708 | 2721 | 3027 | 3001 | 2813 | 2905 | 3070 | 3339 | 3193 | 3460 |
| Operating Profit | 808 | 900 | 1492 | 965 | 1755 | 718 | 787 | 1115 | 829 | 928 |
| Interest | 233 | 248 | 267 | 227 | 236 | 226 | 223 | 212 | 277 | 272 |
| Depreciation | 358 | 389 | 415 | 407 | 405 | 420 | 425 | 436 | 455 | 473 |
| Exceptional Income / Expenses | 0 | -24 | 21 | -9 | 32 | 26 | 18 | 20 | 0 | -12 |
| Profit Before Tax | 217 | 239 | 832 | 322 | 1146 | 98 | 156 | 487 | 97 | 171 |
| Provision for Tax | 35 | 42 | 55 | 96 | 284 | 71 | 75 | 27 | 8 | 39 |
| Profit After Tax | 182 | 197 | 777 | 226 | 862 | 27 | 81 | 459 | 89 | 133 |
| Adjustments | -81 | -71 | -117 | -90 | -202 | -43 | -56 | -115 | -58 | -48 |
| Profit After Adjustments | 101 | 126 | 660 | 136 | 660 | -16 | 25 | 345 | 31 | 85 |
| Adjusted Earnings Per Share | 0.8 | 1 | 5.5 | 1.1 | 5.5 | -0.1 | 0.2 | 2.9 | 0.2 | 0.6 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 3090 | 3347 | 3891 | 4123 | 5514 | 6301 | 7143 | 8184 | 11174 | 14756 | 15262 | 16476 |
| Other Income | 215 | 231 | 285 | 381 | 414 | 508 | 605 | 690 | 768 | 968 | 1356 | 245 |
| Total Income | 3305 | 3579 | 4177 | 4504 | 5929 | 6808 | 7748 | 8874 | 11942 | 15723 | 16618 | 16721 |
| Total Expenditure | 2556 | 2732 | 3040 | 3469 | 4391 | 5044 | 5841 | 6691 | 9055 | 11559 | 12243 | 13062 |
| Operating Profit | 749 | 847 | 1137 | 1035 | 1538 | 1765 | 1907 | 2183 | 2888 | 4164 | 4375 | 3659 |
| Interest | 9 | 29 | 26 | 62 | 71 | 65 | 58 | 68 | 419 | 974 | 897 | 984 |
| Depreciation | 221 | 249 | 277 | 385 | 448 | 552 | 715 | 814 | 1113 | 1569 | 1687 | 1789 |
| Exceptional Income / Expenses | 105 | 161 | 0 | 0 | 195 | 68 | 13 | -111 | -291 | -12 | 97 | 26 |
| Profit Before Tax | 624 | 751 | 850 | 610 | 1215 | 1215 | 1068 | 983 | 897 | 1525 | 1887 | 911 |
| Provision for Tax | 96 | 142 | 162 | 157 | 212 | 315 | 222 | 212 | 254 | 227 | 457 | 149 |
| Profit After Tax | 528 | 609 | 688 | 453 | 1003 | 900 | 846 | 772 | 643 | 1298 | 1429 | 762 |
| Adjustments | -31 | -59 | -76 | -81 | -97 | -152 | -106 | -123 | -180 | -275 | -416 | -277 |
| Profit After Adjustments | 497 | 550 | 612 | 372 | 905 | 748 | 741 | 648 | 463 | 1023 | 1013 | 486 |
| Adjusted Earnings Per Share | 4.1 | 4.6 | 5.1 | 3.1 | 7.5 | 6.2 | 6.2 | 5.4 | 3.9 | 8.5 | 8.4 | 3.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 3% | 23% | 19% | 17% |
| Operating Profit CAGR | 5% | 26% | 20% | 19% |
| PAT CAGR | 10% | 23% | 10% | 10% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 22% | 13% | -1% | 19% |
| ROE Average | 7% | 6% | 8% | 12% |
| ROCE Average | 7% | 7% | 8% | 11% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 3271 | 4034 | 4838 | 5181 | 6098 | 6706 | 7627 | 8433 | 17867 | 19784 | 21644 |
| Minority's Interest | 172 | 266 | 376 | 468 | 609 | 677 | 881 | 1038 | 4622 | 5491 | 6069 |
| Borrowings | 770 | 2072 | 2108 | 1790 | 1526 | 1222 | 2962 | 3999 | 15291 | 12932 | 12405 |
| Other Non-Current Liabilities | 608 | 349 | 196 | 217 | 597 | 1463 | 2535 | 2804 | 5452 | 2187 | 4088 |
| Total Current Liabilities | 1555 | 1666 | 1678 | 2141 | 3039 | 4008 | 4210 | 3828 | 8511 | 15359 | 14334 |
| Total Liabilities | 6375 | 8387 | 9197 | 9796 | 11868 | 14076 | 18215 | 20101 | 51742 | 55753 | 58540 |
| Fixed Assets | 1630 | 1748 | 3625 | 3700 | 4471 | 5971 | 6364 | 6569 | 29468 | 30644 | 31963 |
| Other Non-Current Assets | 2183 | 2667 | 1524 | 1948 | 2508 | 2780 | 4250 | 5149 | 9940 | 9931 | 10290 |
| Total Current Assets | 2563 | 3971 | 4048 | 4149 | 4889 | 5325 | 7600 | 8382 | 12334 | 15179 | 16286 |
| Total Assets | 6375 | 8387 | 9197 | 9796 | 11868 | 14076 | 18215 | 20101 | 51742 | 55753 | 58540 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 557 | 458 | 758 | 710 | 449 | 659 | 825 | 897 | 654 | 1300 | 920 |
| Cash Flow from Operating Activities | 211 | 371 | 640 | 662 | 1155 | 1283 | 1160 | 1177 | 1853 | 2954 | 4061 |
| Cash Flow from Investing Activities | -509 | -1142 | -499 | -684 | -714 | -1559 | -3625 | -1699 | -14282 | -1005 | -234 |
| Cash Flow from Financing Activities | 186 | 1068 | -178 | -240 | -242 | 388 | 2564 | 242 | 13049 | -2333 | -1854 |
| Net Cash Inflow / Outflow | -112 | 297 | -36 | -262 | 199 | 112 | 99 | -280 | 619 | -383 | 1973 |
| Closing Cash & Cash Equivalent | 463 | 758 | 710 | 449 | 659 | 825 | 897 | 654 | 1295 | 920 | 2924 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 4.15 | 4.59 | 5.1 | 3.1 | 7.54 | 6.24 | 6.17 | 5.4 | 3.85 | 8.52 | 8.44 |
| CEPS(Rs) | 6.25 | 7.15 | 8.04 | 6.99 | 12.09 | 12.1 | 13.01 | 13.21 | 14.63 | 23.88 | 25.96 |
| DPS(Rs) | 0.83 | 0.83 | 0.5 | 1 | 0.5 | 0 | 0 | 0.5 | 1.5 | 0.5 | 0.5 |
| Book NAV/Share(Rs) | 26.93 | 33.1 | 39.74 | 42.6 | 50.17 | 54.97 | 62.27 | 68.53 | 146.53 | 162.11 | 176.73 |
| Core EBITDA Margin(%) | 17.11 | 18.22 | 21.71 | 15.85 | 20.38 | 19.95 | 18.23 | 18.18 | 18.8 | 21.41 | 19.68 |
| EBIT Margin(%) | 20.27 | 23.09 | 22.33 | 16.26 | 23.32 | 20.31 | 15.76 | 12.8 | 11.67 | 16.74 | 18.15 |
| Pre Tax Margin(%) | 19.99 | 22.22 | 21.67 | 14.77 | 22.03 | 19.28 | 14.95 | 11.98 | 7.96 | 10.22 | 12.3 |
| PAT Margin (%) | 16.92 | 18.02 | 17.55 | 10.97 | 18.18 | 14.28 | 11.85 | 9.4 | 5.7 | 8.69 | 9.32 |
| Cash Profit Margin (%) | 24 | 25.37 | 24.61 | 20.3 | 26.3 | 23.05 | 21.86 | 19.32 | 15.57 | 19.2 | 20.32 |
| ROA(%) | 8.72 | 8.25 | 7.83 | 4.77 | 9.26 | 6.94 | 5.24 | 4.03 | 1.79 | 2.41 | 2.5 |
| ROE(%) | 17.22 | 16.91 | 15.74 | 9.17 | 18.01 | 14.26 | 12.03 | 9.83 | 4.98 | 7 | 7.03 |
| ROCE(%) | 15.3 | 14.33 | 12.83 | 9.21 | 16.12 | 14.35 | 10.56 | 8.3 | 5.37 | 7.03 | 7.43 |
| Receivable days | 80.09 | 80.16 | 74.35 | 86.05 | 77.96 | 72.86 | 70.03 | 79.49 | 91.14 | 119.85 | 139.43 |
| Inventory Days | 48.47 | 53.71 | 54.81 | 60 | 58.05 | 71.47 | 84.38 | 92.6 | 105.87 | 112.31 | 117.49 |
| Payable days | 112.86 | 146.96 | 170.25 | 194.65 | 212.04 | 231.48 | 230.92 | 209.62 | 271.55 | 376.86 | 450.17 |
| PER(x) | 18.88 | 17.52 | 37.04 | 95.74 | 40.49 | 43.4 | 66.25 | 61.95 | 53.54 | 31.01 | 40.43 |
| Price/Book(x) | 2.91 | 2.43 | 4.75 | 6.97 | 6.09 | 4.92 | 6.57 | 4.88 | 1.41 | 1.63 | 1.93 |
| Dividend Yield(%) | 1.06 | 1.04 | 0.26 | 0.17 | 0.16 | 0 | 0 | 0.15 | 0.73 | 0.19 | 0.15 |
| EV/Net Sales(x) | 3.1 | 3.16 | 6.15 | 8.87 | 6.89 | 5.41 | 7.19 | 5.29 | 3.59 | 3.06 | 3.58 |
| EV/Core EBITDA(x) | 12.78 | 12.49 | 21.05 | 35.35 | 24.71 | 19.32 | 26.93 | 19.85 | 13.9 | 10.85 | 12.48 |
| Net Sales Growth(%) | 7.39 | 8.34 | 16.24 | 5.97 | 33.73 | 14.26 | 13.37 | 14.57 | 36.54 | 32.05 | 3.43 |
| EBIT Growth(%) | 17.35 | 23.32 | 12.18 | -23.32 | 91.48 | -0.47 | -12.06 | -6.64 | 25.26 | 89.92 | 11.38 |
| PAT Growth(%) | 22.66 | 15.27 | 12.97 | -34.15 | 121.28 | -10.25 | -5.96 | -8.82 | -16.67 | 101.84 | 10.14 |
| EPS Growth(%) | 20.2 | 10.66 | 11.21 | -39.16 | 143.1 | -17.35 | -1.03 | -12.48 | -28.64 | 120.99 | -0.9 |
| Debt/Equity(x) | 0.35 | 0.62 | 0.48 | 0.44 | 0.4 | 0.4 | 0.58 | 0.6 | 1.01 | 0.81 | 0.84 |
| Current Ratio(x) | 1.65 | 2.38 | 2.41 | 1.94 | 1.61 | 1.33 | 1.81 | 2.19 | 1.45 | 0.99 | 1.14 |
| Quick Ratio(x) | 1.37 | 2.09 | 2.14 | 1.61 | 1.29 | 0.97 | 1.36 | 1.59 | 0.95 | 0.67 | 0.79 |
| Interest Cover(x) | 71.12 | 26.64 | 33.68 | 10.92 | 18.14 | 19.72 | 19.5 | 15.54 | 3.14 | 2.57 | 3.1 |
| Total Debt/Mcap(x) | 0.12 | 0.26 | 0.1 | 0.06 | 0.07 | 0.08 | 0.09 | 0.12 | 0.72 | 0.5 | 0.43 |
| # | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 60.64 | 60.64 | 60.64 | 60.64 | 60.64 | 60.64 | 60.64 | 60.64 | 54.45 | 54.45 |
| FII | 9.52 | 7.96 | 6.55 | 5.63 | 5.9 | 5.93 | 5.66 | 5.66 | 6.04 | 6.61 |
| DII | 12.59 | 14.08 | 14.51 | 13.68 | 14.3 | 14.44 | 15.36 | 15.72 | 22.82 | 22.1 |
| Public | 17.26 | 17.32 | 18.3 | 20.05 | 19.17 | 19 | 18.34 | 17.97 | 16.68 | 16.83 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 72.8 | 72.8 | 72.8 | 72.8 | 72.8 | 72.8 | 72.8 | 72.8 | 72.8 | 72.8 |
| FII | 11.43 | 9.56 | 7.87 | 6.76 | 7.08 | 7.11 | 6.79 | 6.8 | 8.07 | 8.84 |
| DII | 15.11 | 16.91 | 17.42 | 16.42 | 17.16 | 17.33 | 18.45 | 18.88 | 30.51 | 29.55 |
| Public | 20.72 | 20.79 | 21.97 | 24.07 | 23.01 | 22.81 | 22.02 | 21.58 | 22.31 | 22.51 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 120.06 | 120.06 | 120.06 | 120.06 | 120.06 | 120.06 | 120.06 | 120.06 | 133.7 | 133.7 |
Pros
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | Listing Price | Listing Gain(%) | Current Price | Return (%) | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | Listing Price | Listing Gain(%) | Current Price | Return (%) | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | Listing Price | Listing Gain(%) | Current Price | Return (%) | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | Listing Price | Listing Gain(%) | Current Price | Return (%) | Type | Exchange |
|---|
| Companies | Open Date | Close Date | Issue Price | Cost of 1 Lot | Listing Price | Listing Gain(%) | Current Price | Return (%) | Type | Exchange |
|---|
You May Also Know About
